<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191115045453N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-12-12</date_registration>
      <primary_sponsor>Gorgan University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the Effects of Vaginal Misoprostol, Vaginal Trinitroglycerin (TNG) and oral Evening Primrose Oil in Cervical Ripening at term pregnancy,</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the Effects of Vaginal Misoprostol, Vaginal Trinitroglycerin (TNG) and oral Evening Primrose Oil in Cervical Ripening at term pregnancy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-12-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>201</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/43861</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The participants were randomly assigned to intervention (A) and Control (B) groups in the study by Block Randomization . That is, by using a dice that has 6 funds, samples are assigned to their groups on any form, and each number is assigned to one of the table blocks, which shows its own state.
 Group A (vaginal nitroglycerin) and group B (edible capsule primrose evening) and group C (vaginal misoprostol).  The complete list of random blocks was presented to the principal researcher by the Epidemiological advisor of the study, Blinding description: The implementation of this study is a blind one (single blinding). In this study,  the assessments of the consequences of the study are blind. So that the principal investigator prescribed the drug and the type of group is informed, but the assessment of the consequences for gynecology resident is not in the current purpose of the study and the type of drugs prescribed.</study_design>
      <phase>3</phase>
      <hc_freetext>pregnancy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the intervention group A Pearl TNG Vaginal 400 mg construction of Zahravi company will be prescribed a dose of 4 to 6 hours to 3. Intervention 2: Intervention group: In group B, the capsule of evening primrose evening, 1000 mg capsules of primroses (Barij Essence Company with food and drug verification) will be given every 4 to 6 hours maximum of 3 doses. Intervention 3: Control group: 25 MCG of a misoprostol tablet (a quarter of 100 microgram Mizotak tablets, pharma Abhan) after humidifying the distilled water, every 4th6 hours  in a vaginal form will be administered to 3 doses.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Only part of the data, such as information about the original outcome, or the possibility of sharing.

When:
Start of access period 6 months after printing results

To whom:
Only for researchers working in academic and academic institutions

Conditions:
metanalysis and systematic review

Where to obtain:
investigator through e-mail: sanazalizadehmd@gmail.com

How to obtain:
After receiving the email by the researcher, within 14 business days, the application will be examined and the documentation is provided to the applicant.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sanaz Alizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 3, Alborz St., Ghaemshahr ., Mazandaran, Iran</address>
        <city>Ghaemshahr</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4765694769</zip>
        <telephone>+98 17 3222 4477</telephone>
        <email>sanazalizadehmd@gmail.com</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Sanaz Alizadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 3, Alborz St., Ghaemshahr ., Mazandaran, Iran</address>
        <city>Ghaemshahr</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4765694769</zip>
        <telephone>0098173224477</telephone>
        <email>sanazalizadehmd@gmail.com</email>
        <affiliation>Gorgan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Pregnant women (primigravid)
the term pregnancy (40 weeks onwards)
Bishop Score less or equal to 4
candidate for induction of childbirth</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>History of past uterine surgery
Use of intrauterine contraceptives (IUD)
Any medicinal allergy
Developing systemic and localized infection
Developing known diseases such as diabetes, hypertension and...
Existence of any uterine abnormalities.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the intervention group A Pearl TNG Vaginal 400 mg construction of Zahravi company will be prescribed a dose of 4 to 6 hours to 3.</i_keyword>
      <i_keyword>Intervention group: In group B, the capsule of evening primrose evening, 1000 mg capsules of primroses (Barij Essence Company with food and drug verification) will be given every 4 to 6 hours maximum of 3 doses.</i_keyword>
      <i_keyword>Control group: 25 MCG of a misoprostol tablet (a quarter of 100 microgram Mizotak tablets, pharma Abhan) after humidifying the distilled water, every 4th6 hours  in a vaginal form will be administered to 3 doses</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cervical ripening according to Bishop Score. Timepoint: Before and after 4 hours of intervention. Method of measurement: Bishop's rating table (between 0 and 13).</prim_outcome>
      <prim_outcome>Baby Apgar Score. Timepoint: Minutes One and 5. Method of measurement: Apgar Scoring System (0 to 10).</prim_outcome>
      <prim_outcome>Duration of prescribing medications to childbirth. Timepoint: Time of prescription medication and delivery time. Method of measurement: Based on minutes.</prim_outcome>
      <prim_outcome>Drug side effects. Timepoint: Prescribed time of medication and 4 hours after drug Administration. Method of measurement: Nausea, vomiting, vaginal bleeding, fever and chills, blurred vision, diarrhea, feeling of bitter taste in the mouth, vaginal pain.</prim_outcome>
      <prim_outcome>Vaginal bleeding rate. Timepoint: Postpartum. Method of measurement: It will be measured with a scale of zero to 3 (= 0 = no bleeding, 1 = bleeding), 2 = Low menstrual bleeding, 3 = severe bleeding with clot excretion.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gorgan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-10-09</approval_date>
        <contact_name>Ethics Committee of Golestan University of Medical Sciences</contact_name>
        <contact_address>central organization of Golestan University of Medical Sciences, Hirkan Drive, Gorgan Gorgan Golestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
